Stock TRILC TURK ILAC VE SERUM SANAYI ANONIM SIRKETI
Add to a list
To use this feature you must be a member
Log inSign up

Financials Turk Ilac Ve Serum Sanayi Anonim Sirketi

Equities

TRILC

TRETRLC00022

Pharmaceuticals

Market Closed - Borsa Istanbul
Other stock markets
 16:09:59 14/05/2024 BST 		5-day change 1st Jan Change
31.02 TRY +4.73% Intraday chart for Turk Ilac Ve Serum Sanayi Anonim Sirketi +21.65% +171.39%
04-04 Turk Ilac Ve Serum Sanayi Anonim Sirketi Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Turk Ilac Ve Serum Sanayi Anonim Sirketi Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 1,893 2,181 1,849
Enterprise Value (EV) 1 2,046 2,455 2,267
P/E ratio 51 x 32.9 x 17.5 x
Yield - - -
Capitalization / Revenue 2.81 x 2.62 x 0.97 x
EV / Revenue 3.04 x 2.95 x 1.19 x
EV / EBITDA 25.4 x 31.1 x 7.48 x
EV / FCF -15.9 x -15.7 x 28.2 x
FCF Yield -6.27% -6.35% 3.55%
Price to Book 5.84 x 3.86 x 1.5 x
Nbr of stocks (in thousands) 161,805 161,805 161,805
Reference price 2 11.70 13.48 11.43
Announcement Date 18/02/22 10/02/23 08/04/24
1TRY in Million2TRY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 97.3 152.1 199.5 672.6 833.4 1,913
EBITDA 1 40.8 49.95 76.49 80.61 78.95 303.2
EBIT 1 37.09 45.15 70.17 73.08 69.98 270.7
Operating Margin 38.12% 29.68% 35.17% 10.86% 8.4% 14.15%
Earnings before Tax (EBT) 1 14.51 17.49 40.26 46.86 80.3 82.12
Net income 1 14.39 13.48 33.33 37.14 66.38 105.7
Net margin 14.79% 8.86% 16.71% 5.52% 7.96% 5.53%
EPS 2 0.2742 0.2568 0.2369 0.2295 0.4102 0.6534
Free Cash Flow 1 -19.84 -52.39 -36.47 -128.3 -156 80.49
FCF margin -20.39% -34.44% -18.28% -19.07% -18.72% 4.21%
FCF Conversion (EBITDA) - - - - - 26.54%
FCF Conversion (Net income) - - - - - 76.14%
Dividend per Share - - - - - -
Announcement Date 03/12/20 03/12/20 04/03/21 18/02/22 10/02/23 08/04/24
1TRY in Million2TRY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 60.4 112 128 152 274 418
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.48 x 2.236 x 1.677 x 1.891 x 3.466 x 1.378 x
Free Cash Flow 1 -19.8 -52.4 -36.5 -128 -156 80.5
ROE (net income / shareholders' equity) 26% 21.1% 31.2% 15.7% 14.9% 9.18%
ROA (Net income/ Total Assets) 14.8% 12.4% 13.2% 8.97% 5.26% 8.79%
Assets 1 97.07 109.2 253.2 414.1 1,262 1,203
Book Value Per Share 2 1.190 1.240 1.050 2.000 3.490 7.600
Cash Flow per Share 2 0.1300 0.0300 0 0.2800 0.2300 0.0400
Capex 1 16.2 24.9 16.5 20.6 38.4 79.9
Capex / Sales 16.61% 16.38% 8.29% 3.06% 4.61% 4.17%
Announcement Date 03/12/20 03/12/20 04/03/21 18/02/22 10/02/23 08/04/24
1TRY in Million2TRY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
TURK ILAC VE SERUM SANAYI ANONIM SIRKETI Stock Turk Ilac Ve Serum Sanayi Anonim Sirketi
+171.39% 149M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+31.06% 682B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.35% 586B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.42% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.02% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.27% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.53% 240B
NOVARTIS AG Stock Novartis AG
+10.16% 209B
ROCHE HOLDING AG Stock Roche Holding AG
-8.14% 203B
AMGEN INC. Stock Amgen Inc.
+8.12% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. TRILC Stock
  4. Financials Turk Ilac Ve Serum Sanayi Anonim Sirketi